{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:48:18Z","timestamp":1793998098950,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00402899"],"award-info":[{"award-number":["RS-2024-00402899"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00218648"],"award-info":[{"award-number":["RS-2023-00218648"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00350878"],"award-info":[{"award-number":["RS-2024-00350878"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00242443"],"award-info":[{"award-number":["RS-2023-00242443"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["2E32351-23-130"],"award-info":[{"award-number":["2E32351-23-130"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor natural killer (CAR-NK) cell therapy has emerged as a promising immunotherapeutic modality with potent cytotoxicity and a favorable safety profile. However, its therapeutic efficacy is often limited by poor infiltration into tumors and the profoundly immunosuppressive tumor microenvironment (TME). In hepatocellular carcinoma (HCC), one of the leading causes of cancer-related mortality, this suppressive TME severely compromises the function of CAR-NK cells. To overcome this limitation, we developed a combinatorial strategy integrating irreversible electroporation (IRE), a clinically approved nonthermal ablation modality capable of reshaping the TME, with glypican-3 (GPC3)-targeted CAR-NK cells generated via 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-functionalized lipid nanoparticle (LNP)-mediated gene delivery. IRE promoted immunogenic cell death and reprogrammed the TME through the release of damage-associated molecular patterns and chemokines, notably CX3CL1, thereby enhancing NK cell infiltration. Moreover, IRE-treated HCC cells exhibited heightened susceptibility to NK-mediated cytotoxicity through elevated intracellular reactive oxygen species, establishing a mechanism of immune sensitization. When combined with LNP-engineered GPC3-specific CAR-NK cells, this approach elicited synergistic antitumor activity, as demonstrated by superior tumor lysis in vitro and robust tumor regression in various HCC models without systemic toxicity. By coupling TME remodeling of IRE with the precision and safety of LNP-engineered CAR-NK cells, we propose a durable, clinically actionable treatment paradigm to overcome resistance in solid tumors, such as HCC.<\/jats:p>","DOI":"10.1038\/s41392-026-02627-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:03:14Z","timestamp":1773100994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Joo Dong","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Eun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Su","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehoon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungseok","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hyeok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Gwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-3319","authenticated-orcid":false,"given":"Dong-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4614-0530","authenticated-orcid":false,"given":"Wooram","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2627_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2627_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450\u20131462 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2627_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4254\/wjh.v15.i4.460","volume":"15","author":"YX Gao","year":"2023","unstructured":"Gao, Y. X. et al. Recent advances in recurrent hepatocellular carcinoma therapy. World J. Hepatol. 15, 460\u2013476 (2023).","journal-title":"World J. Hepatol."},{"key":"2627_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2627_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2627_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2627_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B-cell tumors: A phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2627_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3343\/alm.2024.0380","volume":"45","author":"JD Park","year":"2025","unstructured":"Park, J. D. et al. Advancing natural killer cell therapy: Genetic engineering strategies for enhanced cancer immunotherapy. Ann. Lab. Med. 45, 146\u2013159 (2025).","journal-title":"Ann. Lab. Med."},{"key":"2627_CR9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2627_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coche.2017.11.006","volume":"19","author":"J Rosenberg","year":"2018","unstructured":"Rosenberg, J. & Huang, J. CD8(+) T cells and NK cells: Parallel and complementary soldiers of immunotherapy. Curr. Opin. Chem. Eng. 19, 9\u201320 (2018).","journal-title":"Curr. Opin. Chem. Eng."},{"key":"2627_CR11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ccell.2020.09.019","volume":"38","author":"C Turnquist","year":"2020","unstructured":"Turnquist, C. et al. Cytokine storms in cancer and COVID-19. Cancer Cell 38, 598\u2013601 (2020).","journal-title":"Cancer Cell"},{"key":"2627_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/hep.26192","volume":"57","author":"Y Wu","year":"2013","unstructured":"Wu, Y. et al. Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions. Hepatology 57, 1107\u20131116 (2013).","journal-title":"Hepatology"},{"key":"2627_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-024-02106-6","volume":"10","author":"JE Kim","year":"2025","unstructured":"Kim, J. E. et al. Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage. Signal Transduct. Target. Ther. 10, 15 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2627_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.tranon.2019.04.021","volume":"12","author":"S Juengpanich","year":"2019","unstructured":"Juengpanich, S. et al. The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. Transl. Oncol. 12, 1092\u20131107 (2019).","journal-title":"Transl. Oncol."},{"key":"2627_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B. et al. Cold and hot tumors: From molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2627_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jso.23280","volume":"107","author":"R Cannon","year":"2013","unstructured":"Cannon, R. et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J. Surg. Oncol. 107, 544\u2013549 (2013).","journal-title":"J. Surg. Oncol."},{"key":"2627_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","volume":"262","author":"RC Martin","year":"2015","unstructured":"Martin, R. C. et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann. Surg. 262, 486\u2013494 (2015).","journal-title":"Ann. Surg."},{"key":"2627_CR18","doi-asserted-by":"publisher","first-page":"107871","DOI":"10.1016\/j.bioelechem.2021.107871","volume":"141","author":"T Batista Napotnik","year":"2021","unstructured":"Batista Napotnik, T., Polaj\u017eer, T. & Miklav\u010di\u010d, D. Cell death due to electroporation - A review. Bioelectrochemistry 141, 107871 (2021).","journal-title":"Bioelectrochemistry"},{"key":"2627_CR19","doi-asserted-by":"publisher","first-page":"811726","DOI":"10.3389\/fimmu.2021.811726","volume":"12","author":"N Zhang","year":"2021","unstructured":"Zhang, N. et al. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. Front. Immunol. 12, 811726 (2021).","journal-title":"Front. Immunol."},{"key":"2627_CR20","doi-asserted-by":"publisher","first-page":"e48749","DOI":"10.1371\/journal.pone.0048749","volume":"7","author":"X Li","year":"2012","unstructured":"Li, X. et al. Immunologic response to tumor ablation with irreversible electroporation. PLoS One 7, e48749 (2012).","journal-title":"PLoS One"},{"key":"2627_CR21","doi-asserted-by":"publisher","first-page":"e64559","DOI":"10.1371\/journal.pone.0064559","volume":"8","author":"RE Neal","year":"2013","unstructured":"Neal, R. E. et al. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PLoS One 8, e64559 (2013).","journal-title":"PLoS One"},{"key":"2627_CR22","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1002\/mp.12401","volume":"44","author":"PA Garcia","year":"2017","unstructured":"Garcia, P. A. et al. Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. Med. Phys. 44, 4968\u20134980 (2017).","journal-title":"Med. Phys."},{"key":"2627_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202200316","volume":"18","author":"JH Han","year":"2022","unstructured":"Han, J. H. et al. Combination of metal-phenolic network-based immunoactive nanoparticles and bipolar irreversible electroporation for effective cancer immunotherapy. Small 18, e2200316 (2022).","journal-title":"Small"},{"key":"2627_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94016-8","volume":"11","author":"M Lopez-Ichikawa","year":"2021","unstructured":"Lopez-Ichikawa, M. et al. Neutrophils are important for the development of pro-reparative macrophages after irreversible electroporation of the liver in mice. Sci. Rep. 11, 14986 (2021).","journal-title":"Sci. Rep."},{"key":"2627_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1021\/acs.molpharmaceut.4c00006","volume":"21","author":"T Huang","year":"2024","unstructured":"Huang, T. et al. Irreversible electroporation-induced inflammation facilitates neutrophil-mediated drug delivery to enhance pancreatic cancer therapy. Mol. Pharm. 21, 1998\u20132011 (2024).","journal-title":"Mol. Pharm."},{"key":"2627_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11307-021-01669-y","volume":"24","author":"N Sato","year":"2022","unstructured":"Sato, N. & Choyke, P. L. Whole-body imaging to assess cell-based immunotherapy: Preclinical studies with an update on clinical translation. Mol. Imaging Biol. 24, 235\u2013248 (2022).","journal-title":"Mol. Imaging Biol."},{"key":"2627_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/154732804323099235","volume":"13","author":"JM Brand","year":"2004","unstructured":"Brand, J. M. et al. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev. 13, 307\u2013314 (2004).","journal-title":"Stem Cells Dev."},{"key":"2627_CR28","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.adcanc.2022.100069","volume":"6","author":"C Cohen","year":"2022","unstructured":"Cohen, C. et al. CX3CL1 as potential immunotherapeutic tool for bone metastases in lung cancer: A preclinical study. Adv. Cancer Biol. -Metastasis. 6, 100069 (2022).","journal-title":"Adv. Cancer Biol. -Metastasis."},{"key":"2627_CR29","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1182\/blood-2007-08-105965","volume":"111","author":"C Carlino","year":"2008","unstructured":"Carlino, C. et al. Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. Blood 111, 3108\u20133115 (2008).","journal-title":"Blood"},{"key":"2627_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.20032194","volume":"199","author":"K Eleme","year":"2004","unstructured":"Eleme, K. et al. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 199, 1005\u20131010 (2004).","journal-title":"J. Exp. Med."},{"key":"2627_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioelechem.2023.108579","volume":"155","author":"NR Rajagopalan","year":"2024","unstructured":"Rajagopalan, N. R. et al. Electrolysis products, reactive oxygen species and ATP loss contribute to cell death following irreversible electroporation with microsecond-long pulsed electric fields. Bioelectrochemistry 155, 108579 (2024).","journal-title":"Bioelectrochemistry"},{"key":"2627_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/molecules26010154","volume":"26","author":"W Szlasa","year":"2020","unstructured":"Szlasa, W. et al. Oxidative Effects during Irreversible Electroporation of Melanoma Cells-In Vitro Study. Molecules 26, 154 (2020).","journal-title":"Molecules"},{"key":"2627_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2020.12.018","volume":"502","author":"S Sun","year":"2021","unstructured":"Sun, S. et al. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Lett. 502, 9\u201324 (2021).","journal-title":"Cancer Lett."},{"key":"2627_CR34","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/cdd.2014.180","volume":"22","author":"G Jacquemin","year":"2015","unstructured":"Jacquemin, G. et al. Granzyme B-induced mitochondrial ROS are required for apoptosis. Cell Death Differ. 22, 862\u2013874 (2015).","journal-title":"Cell Death Differ."},{"key":"2627_CR35","doi-asserted-by":"publisher","first-page":"e004825","DOI":"10.1136\/jitc-2022-004825","volume":"10","author":"JD Park","year":"2022","unstructured":"Park, J. D. et al. ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. J. Immunother. Cancer 10, e004825 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2627_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen, R., Kang, R. & Tang, D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 54, 91\u2013102 (2022).","journal-title":"Exp. Mol. Med."},{"key":"2627_CR37","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1159\/000492509","volume":"48","author":"M Alnaggar","year":"2018","unstructured":"Alnaggar, M. et al. Allogenic natural killer cell immunotherapy combined with irreversible electroporation for stage IV hepatocellular carcinoma: Survival outcome. Cell. Physiol. Biochem. 48, 1882\u20131893 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"2627_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00270-018-2069-y","volume":"42","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer. Cardiovasc. Interv. Radiol. 42, 48\u201359 (2019).","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"2627_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean, E. M. & McCarthy, H. O. Nonviral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J. Nanobiotechnol. 22, 552 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2627_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202315721","volume":"34","author":"HE Shin","year":"2024","unstructured":"Shin, H. E. et al. Enhancing CAR-NK cells against solid tumors through chemical and genetic fortification with DOTAP-functionalized lipid nanoparticles. Adv. Funct. Mater. 34, 2315721 (2024).","journal-title":"Adv. Funct. Mater."},{"key":"2627_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Herv\u00e1s-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2627_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24132-6","volume":"12","author":"BJ Burbach","year":"2021","unstructured":"Burbach, B. J. et al. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. Nat. Commun. 12, 3862 (2021).","journal-title":"Nat. Commun."},{"key":"2627_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08782-1","volume":"10","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat. Commun. 10, 899 (2019).","journal-title":"Nat. Commun."},{"key":"2627_CR44","doi-asserted-by":"crossref","unstructured":"Go, E. J. et al. Combination of irreversible electroporation and STING agonist for effective cancer immunotherapy. Cancers (Basel). 12, 3123 (2020).","DOI":"10.3390\/cancers12113123"},{"key":"2627_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121762","volume":"289","author":"JH Han","year":"2022","unstructured":"Han, J. H. et al. Image-guided in situ cancer vaccination with combination of multifunctional nanoadjuvant and an irreversible electroporation technique. Biomaterials 289, 121762 (2022).","journal-title":"Biomaterials"},{"key":"2627_CR46","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.7150\/thno.32543","volume":"9","author":"EB Chen","year":"2019","unstructured":"Chen, E. B. et al. The miR-561-5p\/CX(3)CL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CX(3)CR1(+) natural killer cells infiltration. Theranostics 9, 4779\u20134794 (2019).","journal-title":"Theranostics"},{"key":"2627_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.470","volume":"5","author":"ZY Li","year":"2014","unstructured":"Li, Z. Y. et al. IFN-\u03b3 induces aberrant CD49b\u207a NK cell recruitment through regulating CX3CL1: a novel mechanism by which IFN-\u03b3 provokes pregnancy failure. Cell Death Dis. 5, e1512 (2014).","journal-title":"Cell Death Dis."},{"key":"2627_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114175","volume":"275","author":"Z-J Que","year":"2021","unstructured":"Que, Z.-J. et al. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs. J. Ethnopharmacol. 275, 114175 (2021).","journal-title":"J. Ethnopharmacol."},{"key":"2627_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08176-x","volume":"21","author":"X Guo","year":"2021","unstructured":"Guo, X. et al. Immunological effect of irreversible electroporation on hepatocellular carcinoma. BMC Cancer 21, 443 (2021).","journal-title":"BMC Cancer"},{"key":"2627_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jvir.2019.03.002","volume":"30","author":"K Sugimoto","year":"2019","unstructured":"Sugimoto, K. et al. Irreversible electroporation versus radiofrequency ablation: Comparison of systemic immune responses in patients with hepatocellular carcinoma. J. Vasc. Interv. Radiol. 30, 845\u2013853.e846 (2019).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"2627_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10735-024-10223-3","volume":"55","author":"M Summer","year":"2024","unstructured":"Summer, M. et al. Revealing the molecular mechanisms in wound healing and the effects of different physiological factors including diabetes, age, and stress. J. Mol. Histol. 55, 637\u2013654 (2024).","journal-title":"J. Mol. Histol."},{"key":"2627_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 20, 95\u2013112 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2627_CR53","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1535-7163.MCT-12-0093","volume":"11","author":"R Coriat","year":"2012","unstructured":"Coriat, R. et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther. 11, 2284\u20132293 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2627_CR54","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/antiox10091336","volume":"10","author":"B Cucarull","year":"2021","unstructured":"Cucarull, B. et al. Antioxidants threaten multikinase inhibitor efficacy against liver cancer by blocking mitochondrial reactive oxygen species. Antioxid. (Basel) 10, 1336 (2021).","journal-title":"Antioxid. (Basel)"},{"key":"2627_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102250","volume":"6","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell Rep. Med. 6, 102250 (2025).","journal-title":"Cell Rep. Med."},{"key":"2627_CR56","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte, T. et al. Engineering of potent CAR NK cells using nonviral sleeping beauty transposition from minimalistic DNA vectors. Mol. Ther. 32, 2357\u20132372 (2024).","journal-title":"Mol. Ther."},{"key":"2627_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202501475","volume":"15","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Co-delivery of multiple RNAs via lipid nanoparticles enables precise gene editing of CAR-T cells. Adv. Healthc. Mater. 15, e01475 (2025).","journal-title":"Adv. Healthc. Mater."},{"key":"2627_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T-cell engineering. Trends Pharmacol. Sci. 45, 406\u2013418 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2627_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2504950122","volume":"122","author":"N Zhang","year":"2025","unstructured":"Zhang, N. et al. Development of an in situ CAR-T-cell protocol through optical and PSMA-targeted PET imaging. Proc. Natl. Acad. Sci. USA 122, e2504950122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2627_CR60","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724\u20131743 (2016).","journal-title":"Nat. Protoc."},{"key":"2627_CR61","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424\u20131435 (2017).","journal-title":"Nat. Med."},{"key":"2627_CR62","doi-asserted-by":"publisher","unstructured":"Yuan, L. et al. Human assembloids recapitulate periportal liver tissue in vitro. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09884-1 (2025).","DOI":"10.1038\/s41586-025-09884-1"},{"key":"2627_CR63","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1038\/s41596-019-0160-8","volume":"14","author":"JF Dekkers","year":"2019","unstructured":"Dekkers, J. F. et al. High-resolution 3D imaging of fixed and cleared organoids. Nat. Protoc. 14, 1756\u20131771 (2019).","journal-title":"Nat. Protoc."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02627-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:03:16Z","timestamp":1773100996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02627-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2627"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02627-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}